biostudies-literature00550Landreville SNEI NIH HHSNCI NIH HHSNIAMS NIH HHS408-16https://www.ebi.ac.uk/biostudies/studies/S-EPMC3261307biostudies-literatureUnknown18(2)<h4>Purpose</h4>Metastasis is responsible for the death of most cancer patients, yet few therapeutic agents are available which specifically target the molecular events that lead to metastasis. We recently showed that inactivating mutations in the tumor suppressor gene BAP1 are closely associated with loss of melanocytic differentiation in uveal melanoma (UM) and metastasis. The purpose of this study was to identify therapeutic agents that reverse the phenotypic effects of BAP1 loss in UM.<h4>Experimental design</h4>In silico screens were done to identify therapeutic compounds predicted to differentiate UM cells using Gene Set Enrichment Analysis and Connectivity Map databases. Valproic acid (VPA), trichostatin A, LBH-589, and suberoylanilide hydroxamic acid were evaluated for their effects on UM cells using morphologic evaluation, MTS viability assays, bromodeoxyuridine incorporation, flow cytometry, clonogenic assays, gene expression profiling, histone acetylation and ubiquitination assays, and a murine xenograft tumorigenicity model.<h4>Results</h4>Histone deacetylase (HDAC) inhibitors induced morphologic differentiation, cell-cycle exit, and a shift to a differentiated, melanocytic gene expression profile in cultured UM cells. VPA inhibited the growth of UM tumors in vivo.<h4>Conclusions</h4>These findings suggest that HDAC inhibitors may have therapeutic potential for inducing differentiation and prolonged dormancy of micrometastatic disease in UM.Clinical cancer research : an official journal of the American Association for Cancer ResearchHistone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.PMC3261307R01 EY013169R01 CA161870-02P30 EY02687P30 CA091842R01 EY013169-09R01 CA161870R01 CA125970P30 CA91842P30 EY002687R01 CA125970-07R01 EY13169R01 AR050266Onken MDBowcock AMAgapova OAMatatall KAHarbour JWKneass ZTLee RSLandreville S55falseHistone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.<h4>Purpose</h4>Metastasis is responsible for the death of most cancer patients, yet few therapeutic agents are available which specifically target the molecular events that lead to metastasis. We recently showed that inactivating mutations in the tumor suppressor gene BAP1 are closely associated with loss of melanocytic differentiation in uveal melanoma (UM) and metastasis. The purpose of this study was to identify therapeutic agents that reverse the phenotypic effects of BAP1 loss in UM.<h4>Experimental design</h4>In silico screens were done to identify therapeutic compounds predicted to differentiate UM cells using Gene Set Enrichment Analysis and Connectivity Map databases. Valproic acid (VPA), trichostatin A, LBH-589, and suberoylanilide hydroxamic acid were evaluated for their effects on UM cells using morphologic evaluation, MTS viability assays, bromodeoxyuridine incorporation, flow cytometry, clonogenic assays, gene expression profiling, histone acetylation and ubiquitination assays, and a murine xenograft tumorigenicity model.<h4>Results</h4>Histone deacetylase (HDAC) inhibitors induced morphologic differentiation, cell-cycle exit, and a shift to a differentiated, melanocytic gene expression profile in cultured UM cells. VPA inhibited the growth of UM tumors in vivo.<h4>Conclusions</h4>These findings suggest that HDAC inhibitors may have therapeutic potential for inducing differentiation and prolonged dormancy of micrometastatic disease in UM.2012-01-01T00:00:00Z2012 Jan2024-11-21T00:12:12.24Z2019-03-27T00:48:11ZS-EPMC32613072203899410.1158/1078-0432.ccr-11-094610.1158/1078-0432.CCR-11-0946